natgillin/translations-raw huggingface dataset:
This medicine may cause an electrocardiogram (ECG) abnormality demonstrating a long time for an electrical impulse to travel through a certain part of the heart (known as “QT prolongation”). 
To zdravilo lahko povzroči nepravilnost na elektrokardiogramu (EKG), ki se kaže kot podaljšano potovanje impulza skozi določen del srca (imenovano tudi »podaljšanje intervala QT«).
TREVICTA can help alleviate the symptoms of your disease and reduce the chance of your symptoms coming back. 
Zdravilo TREVICTA pomaga lajšati simptome vaše bolezni in preprečuje, da bi se ponovno pojavili.
• loss of menstrual periods, leakage of milk from the breasts 
• izguba menstruacije, iztekanje mleka iz dojk
Improvements in functioning, as measured by the Personal and Social Performance scale (PSP), which was observed during the open-label stabilisation phase were maintained during the double-blind phase for both treatment groups. 
Izboljšanje funkcioniranja preiskovancev, ocenjeno z lestvico osebne in socialne učinkovitosti (Personal and Social Performance Scale, PSP), ki so ga opažali v fazi stabilizacije z odprtim zdravljenjem, se je v obdobju dvojno slepega zdravljenja ohranilo pri preiskovancih v obeh študijskih skupinah.
This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone likely as a result of induction of renal P-gp by carbamazepine. 
To zmanjšanje je v veliki meri povzročeno s 35% povečanjem ledvičnega očistka paliperidona, verjetno zaradi indukcije ledvičnega P-gp s karbamazepinom.
(See Information intended for medical or health care professionals). 
(Glejte Informacije za zdravnike in drugo zdravstveno osebje.)
In this period, 305 symptomatically stable subjects were randomised to continue treatment with TREVICTA (n = 160) or placebo (n = 145) until relapse, early withdrawal, or the end of study. 
V tem obdobju je bilo 305 simptomatsko stabilnih preiskovancev randomiziranih tako, da so nadaljevali zdravljenje z zdravilom TREVICTA (n = 160) ali s placebom (n = 145) do relapsa, predčasne prekinitve ali do zaključka preskušanja.
Safety data involving concomitant use of TREVICTA with other antipsychotics is limited. 
Podatki o varnosti sočasne uporabe zdravila TREVICTA in drugih antipsihotikov so omejeni.
• serious allergic reaction with swelling that may involve the throat and lead to difficulty breathing 
• resna alergijska reakcija z otekanjem, ki lahko zajame grlo in povzroči težave z dihanjem
TREVICTA contains a racemic mixture of (+)- and (-)-paliperidone. 
Zdravilo TREVICTA vsebuje racemat (+) in (-) paliperidona.
Taking this medicine with carbamazepine (an anti-epileptic and mood stabiliser) may require a change to your dose of this medicine. 
Zaradi sočasnega jemanje tega zdravila s karbamazepinom (ki je zdravilo proti epilepsiji in stabilizator razpoloženja) bo morda treba prilagoditi odmerjanje tega zdravila.
Refer to ‘Hyperprolactinaemia' below. 
Glejte “hiperprolaktinemija” spodaj.
Concomitant use of TREVICTA with psychostimulants 
Sočasna uporaba zdravila TREVICTA in psihostimulansov
Based on the investigators' ratings, induration, redness, and swelling were absent or mild in ≥ 95% of the assessments. 
Po oceni raziskovalcev so bile induracija, rdečina in oteklina blago izražene ali odsotne v ≥ 95%.
After shaking the syringe for at least 15 seconds, check the appearance of the suspension in the viewing window. 
Po stresanju, ki naj traja najmanj 15 sekund, preverite izgled suspenzije v preglednem okencu.
You should not stop using this medicine unless told to do so by your doctor. 
Uporabe tega zdravila ne smete prekiniti, razen če vam je to naročil zdravnik.
• low blood pressure, low blood pressure upon standing (consequently, some people taking this medicine may feel faint, dizzy, or may pass out when they stand up or sit up suddenly) 
• nizek krvni tlak, nizek krvni tlak, ko vstanete (zato lahko nekateri ljudje, ki prejemajo to zdravilo, občutijo omedlevico, omotico ali pa se ob hitrem vstajanju ali vsedanju iz ležečega položaja zgrudijo)
Physicians should weigh the risks versus the benefits when prescribing TREVICTA to patients with Parkinson's disease or Dementia with Lewy Bodies (DLB) since both groups may be at increased risk of Neuroleptic Malignant Syndrome as well as having an increased sensitivity to antipsychotics. 
Zdravnik mora pretehtati tveganja in koristi predpisovanja zdravila TREVICTA bolnikom s Parkinsonovo boleznijo ali z demenco z Lewyjevimi telesci, ker imata obe skupini lahko povečano tveganje za pojav nevroleptičnega malignega sindroma in tudi povečano občutljivost na antipsihotike.
The time to relapse of the placebo group (median 395 days) was significantly shorter than for the TREVICTA group (the median could not be estimated due to the low percentage of subjects with relapse [8.8%]). 
Čas do relapsa je bil pomembno krajši v skupini s placebom (mediano 395 dni) v primerjavi s skupino, ki je prejemala zdravilo TREVICTA (mediane časa do relapsa ni bilo mogoče oceniti zaradi nizkega odstotka preiskovancev z relapsom [8,8%]).
Information intended for medical or health care professionals 
Informacije za zdravnike in drugo zdravstveno osebje
In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of medicines metabolised by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. 
Študije in vitro na človeških jetrnih mikrosomih so pokazale, da paliperidon bistveno ne zavira presnove zdravil, ki se presnavljajo z izoencimi citokroma P450, vključno s CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4 in CYP3A5.
The needle is secure when a “click” sound is heard. 
Injekcijska igla je ustrezno zaščitena, ko zaslišite »klik«.
C-paliperidone, 59% of the dose was excreted unchanged into urine, indicating that paliperidone is not extensively metabolised in the liver. 
C-paliperidona s takojšnjim sproščanjem se je 59% odmerka izločilo nespremenjenega z urinom, kar kaže, da se paliperidon v jetrih ne presnavlja v veliki meri.
Elimination of paliperidone decreased with decreasing estimated creatinine clearance. 
Izločanje paliperidona se je zmanjševalo skladnoz oceno zmanjševanja očistka kreatinina.
• white blood cell count decreased, decrease in the type of white blood cells that help to protect you against infection, decrease in platelets (blood cells that help you stop bleeding), anaemia 
• zmanjšano število belih krvnih celic, zmanjšano število vrste belih krvnih celic, ki vas pomagajo varovati pred okužbami, zmanjšano število trombocitov (krvnih ploščic, ki omogočajo ustavljanje krvavitve), slabokrvnost (anemija)
Even though paliperidone is a strong D2-antagonist, which is believed to relieve the symptoms of schizophrenia, it causes less catalepsy and decreases motor functions less than traditional neuroleptics. 
Čeprav je paliperidon močan antagonist D2 in menijo, da tako ublaži pozitivne simptome shizofrenije, v primerjavi s klasičnimi nevroleptiki povzroči manj katalepsije in manj oslabi motorično funkcijo.
Following administration of TREVICTA, the (+) and (-) enantiomers of paliperidone interconvert, reaching an AUC (+) to (-) ratio of approximately 1.7-1.8. 
Po odmerjanju zdravila TREVICTA se (+) in (-) enantiomer paliperidona pretvarjata eden v drugega tako, da je razmerje AUC med (+) in (-) enantiomerom približno 1,7 do 1,8.
A population pharmacokinetic analysis based on data with oral paliperidone prolonged release tablets showed a slightly lower exposure to paliperidone in smokers compared with non-smokers. 
Analiza farmakokinetike populacije podatkov na osnovi peroralnega paliperidona v obliki tablet s podaljšanim sproščanjem je pokazala nekoliko manjšo izpostavljenost paliperidonu pri kadilcih kot pri nekadilcih.
If you have responded well to treatment with paliperidone palmitate injection given once a month, your doctor may start treatment with TREVICTA. 
Če ste se dobro odzvali na zdravljenje z injekcijami paliperidonijevega palmitata, ki ste jih prejemali enkrat na mesec, vas bo zdravnik lahko začel zdraviti z zdravilom TREVICTA.
In general, recommended dosing of TREVICTA for elderly patients with normal renal function is the same as for younger adult patients with normal renal function. 
Priporočeno odmerjanje zdravila TREVICTA pri starejših bolnikih z normalnim delovanjem ledvic je enako kot pri mlajših odraslih bolnikih z normalnim delovanjem ledvic.
• atrial fibrillation (an abnormal heart rhythm), irregular heart beat 
• atrijska fibrilacija (motnja srčnega ritma), nepravilen srčni utrip
Negative means a lack of behaviours or feelings that are normally present. 
Negativni simptomi odražajo pomanjkanje normalnih občutkov ali vedenja.
• are a man and experience prolonged or painful erection. 
• ste moški in se pri vas pojavi dolgotrajna ali boleča erekcija, ki se imenuje priapizem.
However, elderly patients with dementia, who are treated with other similar types of medicine, may have an increased risk of stroke or death (see section 4). 
Pri starejših bolnikih z demenco, ki se zdravijo s podobnimi zdravili, pa je tveganje za možgansko kap in smrt lahko povečano (glejte poglavje 4).
While it can involve any part of the body (and may result in abnormal posture), dystonia often involves muscles of the face, including abnormal movements of the eyes, mouth, tongue or jaw. 
Čeprav lahko distonija vključuje katerikoli del telesa (lahko povzroči nenormalno telesno držo), se pogosto pojavi na mišicah obraza, vključno z nenormalnimi gibi očesa, ust, jezika ali čeljusti.
The hazard ratio was 3.81 (95% CI: 2.08, 6.99) indicating a 74% decrease in relapse risk with TREVICTA compared to placebo. 
Razmerje ogroženosti 3,81 (95% IZ: 2,08, 6,99) nakazuje, da je bilo pri uporabi zdravila TREVICTA tveganje za relaps zmanjšano za 74% v primerjavi s tveganjem pri uporabi placeba.
Refer to ‘Extrapyramidal symptoms' below. 
Glejte “ekstrapiramidni simptomi” spodaj.
The release profile and dosing regimen of TREVICTA results in sustained therapeutic concentrations. 
Profil sproščanja in režim odmerjanja zdravila TREVICTA omogočata dolgotrajno ohranjanje terapevtskih koncentracij.
• swelling of the face, mouth, eyes, or lips, swelling of the body, arms, or legs 
• otekanje obraza, ust, oči ali ustnic, otekline po telesu, rokah ali nogah
Following a single intramuscular dose of TREVICTA, the plasma concentrations of paliperidone gradually rise to reach maximum plasma concentrations at a median Tmax of 30-33 days. 
Po intramuskularnem injiciranju enkratnih odmerkov zdravila TREVICTA se koncentracija paliperidona v plazmi postopoma povišuje in doseže najvišjo koncentracijo v plazmi v medianem času Tmax 30-33 dni.
The plasma protein binding of racemic paliperidone is 74%. 
Vezava racemnega paliperidona na plazemske beljakovine je 74%.
Inject slowly, deep into the muscle taking care to avoid injection into a blood vessel. 
Zdravilo injicirajte počasi, globoko v mišico in pazite, da ga ne injicirate v krvno žilo.
Full instructions for use and handling of TREVICTA are provided in the package leaflet (See Information intended for medical or health care professionals). 
Natančna navodila za uporabo in ravnanje z zdravilom TREVICTA so v navodilu za uporabo (glejte Informacije za zdravnike in drugo zdravstveno osebje).
12 mg * All doses of once daily paliperidone prolonged release tablets should be individualised to the specific patient, taking into consideration variables such as reasons for switching, response to previous paliperidone treatment, severity of psychotic symptoms, and/or propensity for side effects. 
12 mg * Odmerjanje tablet paliperidona s podaljšanim sproščanjem enkrat na dan je treba prilagoditi posameznemu bolniku in upoštevati dejavnike, kot so razlogi za zamenjavo, odziv na predhodno zdravljenje s paliperidonom, izraženost psihotičnih simptomov in/ali dovzetnost za neželene učinke.
Other medicines and TREVICTA Tell your doctor if you are taking, have recently taken or might take any other medicines. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Recommended re-initiation regimen after missing 4 months to 9 months of TREVICTA 
Priporočena shema ponovne uvedbe zdravljenja po 4 do 9 mesecih izpuščanja odmerkov zdravila TREVICTA
It is also normal to see small air bubbles. 
Če opazite majhne zračne mehurčke, je to povsem normalno.
Since no effect on the systemic clearance was observed, a clinically significant interaction would not be expected between divalproex sodium prolonged release tablets and TREVICTA intramuscular injection. 
Ker niso opazili nobenega učinka na sistemski očistek, ne pričakujejo klinično pomembne interakcije med tabletami natrijevega divalproeksa s podaljšanim sproščanjem in intramuskularno injiciranim zdravilom TREVICTA.
However, in the event of an incompletely injected dose, the dose remaining in the syringe should not be re-injected and another dose should not be given since it is difficult to estimate the proportion of the dose actually administered. 
Če odmerek ni bil injiciran v celoti, bolniku naknadno ne smemo injicirati preostanka vsebine v injekcijski brizgi ali novega odmerka, saj je težko oceniti, kolikšen del odmerka je bolnik dejansko prejel.
The patient should be closely monitored and managed as clinically appropriate until the next scheduled 3-monthly injection of TREVICTA. 
Bolnika je treba skrbno spremljati in zdraviti v skladu s kliničnimi potrebami do naslednjega rednega odmerka 3-mesečne injekcije zdravila TREVICTA.
TREVICTA should be administered by a healthcare professional as a single injection. 
Zdravilo TREVICTA smejo zdravstveni delavci aplicirati samo kot enkratno injekcijo.
If you stop receiving your injections, your symptoms of schizophrenia may get worse. 
Če ste prenehali uporabljati zdravilo TREVICTA Če prenehate prejemati injekcije, se lahko simptomi shizofrenije poslabšajo.
Thin wall safety needles are designed specifically for use with TREVICTA. 
Varnostne igle s tanko steno so oblikovane posebej za uporabo z zdravilom TREVICTA.
TREVICTA is not recommended in patients with moderate or severe renal impairment (creatinine clearance < 50 mL/min). 
Uporaba zdravila TREVICTA ni priporočljiva pri bolnikih z zmerno ali hudo okvaro ledvic (z očistkom kreatinina < 50 ml/min).
• increase in eosinophils (a type of white blood cell) in your blood 
• povečano število eozinofilcev (vrsta belih krvnih celic) v krvi
Prepare for injection 
Priprava na injiciranje
What TREVICTA is and what it is used for What you need to know before you use TREVICTA How to use TREVICTA 
Kaj je zdravilo TREVICTA in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo TREVICTA Kako uporabljati zdravilo TREVICTA Možni neželeni učinki
The following information is intended for medical or healthcare professionals only and should be read by the medical or healthcare professional in conjunction with the full prescribing information (Summary of Product Characteristics). 
Zdravniki in drugi zdravstveni delavci naj te informacije preberejo skupaj z informacijami za predpisovanje (povzetek glavnih značilnosti zdravila).
• TREVICTA can raise your levels of a hormone called "prolactin" found on a blood test (which may or may not cause symptoms). 
• Zdravilo TREVICTA lahko v krvnih preiskavah poviša koncentracije hormona, ki ga imenujemo ''prolaktin'' (kar lahko povzroči simptome ali pa ne).
TREVICTA should be used with caution with medicines that increase the activity of the central nervous system (psychostimulants such as methylphenidate). 
Pri sočasni uporabi zdravila TREVICTA z zdravili, ki povečajo aktivnost centralnega živčnega sistema (psihostimulansi, kot je metilfenidat), je potrebna previdnost.
Based on in vitro studies utilising human liver enzymes, paliperidone is not a substrate for CYP1A2; smoking should, therefore, not have an effect on the pharmacokinetics of paliperidone. 
Na podlagi študij in vitro, v katerih so uporabili humane jetrne encime, paliperidon ni substrat za encim CYP1A2, zato kajenje ne bi smelo vplivati na farmakokinetiko paliperidona.
- if you have Parkinson's disease - if you have ever been diagnosed with a condition whose symptoms include high temperature and muscle stiffness (also known as Neuroleptic Malignant Syndrome) - if you have ever experienced twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body (Tardive Dyskinesia) - if you know that you have had low levels of white blood cells in the past (which may or may not have been caused by other medicines) - if you are diabetic or prone to diabetes - if you have had breast cancer or a tumour in the pituitary gland in your brain - if you have a heart disease or heart disease treatment that makes you prone to low blood pressure - if you have low blood pressure when you stand up or sit up suddenly - if you have a history of seizures - if you have kidney problems - if you have liver problems - if you have prolonged and/or painful erection - if you have problems with controlling body temperature or overheating - if you have an abnormally high level of the hormone prolactin in your blood or if you have a possible prolactin-dependent tumour - if you or someone else in your family has a history of blood clots, as antipsychotics have been associated with formation of blood clots. 
- če imate Parkinsonovo bolezen - če so vam kdaj diagnosticirali stanje s simptomi, kot sta povišana telesna temperatura in mišična okorelost (znano tudi kot nevroleptični maligni sindrom) - če so se pri vas kadar koli pojavili sunkoviti gibi ali trzljaji obraza, jezika ali drugih delov telesa, ki jih niste mogli nadzorovati (tardivna diskinezija) - če ste že imeli majhno število belih krvnih celic (ki bi jo lahko ali ne povzročilo drugo zdravilo) - če imate sladkorno bolezen ali ste nagnjeni k sladkorni bolezni - če ste imeli raka dojke ali tumor hipofize v možganih - če imate srčno bolezen ali se zdravite za srčne bolezni in ste zato nagnjeni k nizkemu krvnemu tlaku - če imate nizek krvni tlak, kadar nenadoma vstanete ali se usedete iz ležečega položaja - če ste imeli epileptične krče - če imate težave z ledvicami - če imate težave z jetri - če imate podaljšano in/ali bolečo erekcijo - če imate težave z nadzorovanjem telesne temperature ali se hitro pregrejete - če imate nenormalno visoke koncentracije hormona prolaktina v krvi ali imate tumor, ki je odvisen od prolaktina - če ste imeli vi ali kdo drug v vaši družini krvne strdke, saj je jemanje antipsihotikov povezano z nastankom krvnih strdkov
Patients treated with TREVICTA should be monitored for symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus should be monitored regularly for worsening of glucose control. 
Bolnike, ki prejemajo zdravilo TREVICTA, je treba spremljati glede simptomov hiperglikemije (kot so polidipsija, poliurija, polifagija in šibkost) ter redno spremljati bolnike s sladkorno boleznijo glede poslabšanja nadzora koncentracije glukoze v krvi.
Following the initial TREVICTA dose, TREVICTA should be administered by intramuscular injection once every 3 months (± 2 weeks, see also Missed dose section). 
Po začetnem odmerku zdravila TREVICTA je treba zdravilo injicirati intramuskularno enkrat na 3 mesece (± 2 tedna, glejte tudi poglavje Izpuščeni odmerki).
If needed, dose adjustment of TREVICTA can be made every 3 months in increments within the range of 175 mg to 525 mg based on individual patient tolerability and/or efficacy. 
Po potrebi se lahko odmerke zdravila TREVICTA postopno prilagaja vsake 3 mesece v razponu odmerkov od 175 mg do 525 mg, odvisno od prenašanja in/ali učinkovitosti zdravila pri posameznem bolniku.
• have dementia and experience a sudden change in your mental state or sudden weakness or numbness of your face, arms or legs, especially on one side, or slurred speech, even for a short period of time. 
• imate demenco in opazite nenadne spremembe svojega duševnega stanja ali nenadno šibkost ali odrevenelost obraza, rok ali nog, zlasti če se to pojavi samo na eni strani telesa, ali nerazločnost govora, četudi samo za kratek čas.
Do not administer by any other route. 
Ne injicirajte na noben drug način.
Seek medical attention right away if you experience a rash, swelling of your throat, itching, or problems breathing as these may be signs of a serious allergic reaction. 
Če opazite izpuščaj, vam oteče grlo, vas srbi ali imate težave z dihanjem, takoj poiščite zdravniško pomoč, ker so to lahko znaki hude alergijske reakcije.
The most frequently observed adverse drug reactions reported in ≥ 5% of patients in two double-blind controlled clinical trials of TREVICTA were weight increased, upper respiratory tract infection, anxiety, headache, insomnia, and injection site reaction. 
Najpogostejši neželeni učinki, o katerih so poročali pri ≥ 5% bolnikov v dveh dvojno slepih nadzorovanih kliničnih preskušanjih zdravila TREVICTA, so bili povečanje telesne mase, okužba zgornjih dihal, tesnoba, glavobol, nespečnost in reakcija na mestu injiciranja zdravila.
Do not save for future use. 
Ne smete je shraniti za kasnejšo uporabo.
Regardless of patient weight: yellow hub 
Neodvisno od bolnikove telesne mase: rumeni nastavek
The difference (95% CI) between the treatment groups was 1.2% (-2.7%, 5.1%), meeting non-inferiority criterion based on a margin of -10%. 
Ta odstotek se je med skupinama razlikoval za 1,2% (95-odstotni interval zaupanja -2, %, 5,1%), s čimer je bil izpolnjen kriterij za neinferiornost, ki ga je določal prag razlike -10%.
Paliperidone is not expected to cause clinically important pharmacokinetic interactions with medicinal products that are metabolised by cytochrome P450 isozymes. 
Ni pričakovati, da bi paliperidon povzročil klinično pomembne farmakokinetične interakcije z zdravili, ki se presnavljajo z izoencimi citokroma P450.
TREVICTA should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold. 
Zdravilo TREVICTA je treba uporabljati previdno pri bolnikih z epileptičnimi napadi v anamnezi ali z drugimi stanji, ki lahko znižajo prag za epileptični napad.
Potential for TREVICTA to affect other medicines 
Možnost, da bo zdravilo TREVICTA vplivalo na druga zdravila
Dizziness, extreme tiredness and vision problems may occur during treatment with this medicine (see section 4). 
Med zdravljenjem s tem zdravilom se lahko pojavijo omotica, izčrpanost in težave z vidom (glejte poglavje 4).
Consideration should be given to the long-acting nature of TREVICTA. 
Upoštevati je treba podaljšano delovanje zdravila TREVICTA.
Slowly inject the entire contents of the syringe intramuscularly, deep into the selected deltoid or gluteal muscle. 
Celotno vsebino injekcijske brizge intramuskularno injicirajte počasi, globoko v izbrano deltoidno ali glutealno mišico.
The primary efficacy endpoint of the study was the percentage of subjects who had not relapsed at the end of the 48-week double-blind phase based on the Kaplan-Meier 48-week estimate (TREVICTA: 91.2%, 1-monthly paliperidone palmitate injectable: 90.0%). 
Primarni cilj učinkovitosti v študiji je bil odstotek preiskovancev, pri katerih do konca 48-tedenskega obdobja dvojno slepega zdravljenja ni prišlo do relapsa na osnovi Kaplan-Meierjeve ocene v 48 tednih (zdravilo TREVICTA: 91,2%, 1-mesečne injekcije paliperidonijevega palmitata: 90,0%).
On initiation of carbamazepine, the dose of TREVICTA should be re-evaluated and increased if necessary. 
Ob uvajanju karbamazepina je treba odmerek zdravila TREVICTA ponovno oceniti in ga po potrebi povečati.
The dose could be adjusted (i.e., 50 mg, 75 mg, 100 mg, or 150 mg) at the week 5 and 9 injections and the injection site could be deltoid or gluteal. 
Odmerke so lahko prilagajali (50 mg, 75 mg, 100 mg ali 150 mg) ob injiciranju zdravila v 5. in po 9. tednu, injicirali pa so jih v deltoidno ali glutealno mišico.
Conversely, on discontinuation of carbamazepine, the dose of TREVICTA should be re-evaluated and decreased if necessary. 
Ob ukinitvi karbamazepina je treba odmerek zdravila TREVICTA ponovno oceniti in po potrebi zmanjšati.